Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Sarcoma, Ewing 1 Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1 HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer 1 Chondrosarcoma 1

Interventions

Cyclophosphamide 37 Etoposide 25 Vincristine 24 Cytarabine 21 Doxorubicin 19 Rituximab 17 Radiotherapy 17 Peripheral Blood Stem Cell Transplantation 16 Melphalan 16 Prednisolone 14 Methotrexate 14 Filgrastim 13 fludarabine phosphate 11 Prednisone 11 Dexamethasone 11 Carmustine 9 Bleomycin 9 pegylated granulocyte colony-stimulating factor 8 Cyclosporine 8 Busulfan 8 fludarabine 7 Ifosfamide 7 Cisplatin 7 sargramostim 6 Vinblastine 6 Mitoxantrone 6 Methylprednisolone 6 Gemcitabine 6 Chlorambucil 6 Antilymphocyte Serum 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma × TQ-B3525 × Clear all

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡